References
- Hayes MT. Parkinson’s disease and parkinsonism. Am J Med. 2019;132(7):802–807.
- Cabreira V, Massano J. Clinical review and update. Acta Med Port. 2019;32(10):661–670. [Parkinson’s Disease
- Tysnes OB, Storstein A. Epidemiology of Parkinson’s disease. J Neural Transm (Vienna). 2017;124(8):901–905.
- Voet S, Prinz M, van Loo G. Microglia in central nervous system inflammation and multiple sclerosis pathology. Trends Mol Med. 2019;25(2):112–123.
- Gogoleva VS, Drutskaya MS, Atretkhany KS. The role of microglia in the homeostasis of the central nervous system and neuroinflammation. Mol Biol (Mosk). 2019;53(5):790–798.
- Mesquida-Veny F, Del Rio JA, Hervera A. Macrophagic and microglial complexity after neuronal injury. Prog Neurobiol. 2021;200:101970.
- Tang Y, Le W. Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol Neurobiol. 2016;53(2):1181–1194.
- Devanney NA, Stewart AN, Gensel JC. Microglia and macrophage metabolism in CNS injury and disease: the role of immunometabolism in neurodegeneration and neurotrauma. Exp Neurol. 2020;329:113310.
- Singh A, Kukreti R, Saso L, et al. Oxidative stress: a key modulator in neurodegenerative diseases. Molecules. 2019. 242019. 1583.
- Buvelot H, Jaquet V, Krause KH. Mammalian NADPH oxidases. Methods Mol Biol. 2019;1982:17–36.
- Zeng MY, Miralda I, Armstrong CL, et al. The roles of NADPH oxidase in modulating neutrophil effector responses. Mol Oral Microbiol. 2019;34(2):27–38.
- Belambri SA, Rolas L, Raad H, et al. NADPH oxidase activation in neutrophils: role of the phosphorylation of its subunits. Eur J Clin Invest. 2018;48(Suppl 2):e12951.
- Trevelin SC, Shah AM, Lombardi G. Beyond bacterial killing: NADPH oxidase 2 is an immunomodulator. Immunol Lett. 2020;221:39–48.
- Du L, Zhang Y, Chen Y, et al. Role of microglia in neurological disorders and their potentials as a therapeutic target. Mol Neurobiol. 2017;54(10):7567–7584.
- Werry EL, Bright FM, Piguet O, et al. Recent developments in TSPO PET imaging as a biomarker of neuroinflammation in neurodegenerative disorders. Int J Mol Sci. 2019. 202019. 3161.
- Lee Y, Park Y, Nam H, et al. Translocator protein (TSPO): the new story of the old protein in neuroinflammation. BMB Rep. 2020;53(1):20–27.
- Best L, Ghadery C, Pavese N, et al. New and old TSPO PET radioligands for imaging brain microglial activation in neurodegenerative disease. Curr Neurol Neurosci Rep. 2019;19(5):24.
- Gavish M, Veenman L. Regulation of mitochondrial, Cellular, and organismal functions by TSPO. Adv Pharmacol. 2018;82:103–136.
- Shang C, Yao RM, Guo Y, et al. Translocator protein-mediated fast-onset antidepressant-like and memory-enhancing effects in chronically stressed mice. J Psychopharmacol. 2020;34(4):441–451.
- Loth MK, Guariglia SR, Re DB, et al. A novel interaction of translocator protein 18 kDa (TSPO) with NADPH oxidase in Microglia. Mol Neurobiol. 2020;57(11):4467–4487.
- Belloli S, Morari M, Murtaj V, et al. Translation imaging in Parkinson’s disease: focus on neuroinflammation. Front Aging Neurosci. 2020;12:152.
- Tu H, Ma D, Luo Y, et al. Quercetin alleviates chronic renal failure by targeting the PI3k/Akt pathway. Bioengineered. 2021;12(1):6538–6558.
- Jiang L, Zuo Z, Lin J, et al. Orthodenticle homeobox OTX1 is a potential prognostic biomarker for bladder cancer. Bioengineered. 2021;12(1):6559–6571.
- Wang Q, Pan Y, Zhao L, et al. Protein tyrosine phosphatase 1B(PTP1B) promotes melanoma cells progression through Src activation. Bioengineered. 2021;12(1):8396–8406.
- Setiawan E, Wilson AA, Mizrahi R, et al. Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry. 2015;72(3):268–275.
- Costa B, Da Pozzo E, Martini C. 18-kDa translocator protein association complexes in the brain: from structure to function. Biochem Pharmacol. 2020;177:114015.
- Chauveau F, Becker G, Boutin H. Have (R)-[(11)C]PK11195 challengers fulfilled the promise? A scoping review of clinical TSPO PET studies. Eur J Nucl Med Mol Imaging. 2021;49(1):201–220.
- Choi J, Ifuku M, Noda M, et al. Translocator protein (18 kDa)/peripheral benzodiazepine receptor specific ligands induce microglia functions consistent with an activated state. Glia. 2011;59(2):219–230.
- Guilarte TR, Loth MK, Guariglia SR. TSPO finds NOX2 in Microglia for redox homeostasis. Trends Pharmacol Sci. 2016;37(5):334–343.
- Barron AM, Garcia-Segura LM, Caruso D, et al. Ligand for translocator protein reverses pathology in a mouse model of Alzheimer’s disease. J Neurosci. 2013;33(20):8891–8897.
- Li M, Ren H, Sheth KN, et al. A TSPO ligand attenuates brain injury after intracerebral hemorrhage. FASEB J. 2017;31(8):3278–3287.
- Juhas U, Ryba-Stanislawowska M, Szargiej P, et al. Different pathways of macrophage activation and polarization. Postepy Hig Med Dosw (Online). 2015;69:496–502.
- Xu Y, Shen J, Ran Z. Emerging views of mitophagy in immunity and autoimmune diseases. Autophagy. 2020;16(1):3–17.
- Kanazawa M, Ninomiya I, Hatakeyama M, et al. Microglia and Monocytes/Macrophages polarization reveal novel therapeutic mechanism against stroke. Int J Mol Sci. 2017. 182017. 2135.
- Gatliff J, East DA, Singh A, et al. A role for TSPO in mitochondrial Ca(2+) homeostasis and redox stress signaling. Cell Death Dis. 2017;8(6):e2896.
- Labandeira-Garcia JL, Rodriguez-Perez AI, Garrido-Gil P, et al. Brain renin-angiotensin system and microglial polarization: implications for aging and neurodegeneration. Front Aging Neurosci. 2017;9:129.
- Wang J, Ma MW, Dhandapani KM, et al. Regulatory role of NADPH oxidase 2 in the polarization dynamics and neurotoxicity of microglia/macrophages after traumatic brain injury. Free Radic Biol Med. 2017;113:119–131.
- Zhu X, Zhao P, Lu Y, et al. Potential injurious effects of the fine particulate PM2.5 on the progression of atherosclerosis in apoE-deficient mice by activating platelets and leukocytes. Arch Med Sci. 2019;15(1):250–261.
- Jiang T, Sun Q, Chen S. Oxidative stress: a major pathogenesis and potential therapeutic target of antioxidative agents in Parkinson’s disease and Alzheimer’s disease. Prog Neurobiol. 2016;147:1–19.
- Wang X, Saegusa H, Huntula S, et al. Blockade of microglial Cav1.2 Ca(2+) channel exacerbates the symptoms in a Parkinson’s disease model. Sci Rep. 2019;9(1):9138.
- Liu CY, Wang X, Liu C, et al. Pharmacological targeting of microglial activation: new therapeutic approach. Front Cell Neurosci. 2019;13:514.
- Han C, Xiong N, Guo X, et al. Exosomes from patients with Parkinson’s disease are pathological in mice. J Mol Med (Berl). 2019;97(9):1329–1344.